Latest MS research news

Latest MS research news | 08 April 2014

JC virus reactivation during prolonged natalizumab monotherapy for MS

This study looks at getting a better understanding of the virus which causes PML (Progressive Multifocal Leucoencephalopathy) in patients treated with natalizumab (tysabri).

From MSIF

Latest MS research news | 08 April 2014

Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial

This study shows that natalizumab (tysabri) treatment in progressive MS reduces central nervous system (CNS) inflammation and tissue damage.

From MSIF

Latest MS research news | 01 April 2014

Composite end points to assess delay of disability progression by MS treatments

Monitoring progression of disease in MS can be difficult particularly in clinical trials. The Expanded Disability Status Scale (EDSS) is most commonly used. The results from this study showed that using composite end points (combination of two or more end points) such as the timed-25 foot walk test and the nine-hole peg test may be better than using the EDSS alone in monitoring disease progression.

From MSIF

Latest MS research news | 01 April 2014

Posterior brain damage and cognitive impairment in paediatric MS

Paediatric patients with MS can experience cognitive impairment, with a prominent involvement of linguistic abilities in addition to memory, attention and executive function. This study looked at improving our understanding of the mechanisms involved in memory difficulties in paediatric patients with MS. Overall, the results showed that the posterior regions of the brain were most likely to be abnormal on structural and functional MRI.

From MSIF

Latest MS research news | 31 March 2014

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive MS (MS-STAT)

This phase 2, placebo-controlled trial showed that statins (simvastatin) in secondary progressive MS were safe, well tolerated and reduced progression of annualised brain atrophy over two years.

From MSIF

Latest MS research news | 25 March 2014

Core outcome measures for exercise studies in people with MS

The results of a meeting of a group of international experts, which recommended the most appropriate outcome measures for use in exercise-based research as one step in the process toward the application, and evaluation, of exercise in people with MS.

From MSIF

Latest MS research news | 25 March 2014

Tracking changes over time in retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness in MS

Eyes of people with MS provide a unique opportunity to study axonal degeneration. The study showed that there was progressive neuronal loss in patients in the absence of clinically evident inflammation in the eyes.

From MSIF

Latest MS research news | 24 March 2014

Serum phosphorylated neurofilament-heavy chain levels in MS patients

This study looked at a particular type of protein in the blood of patients with MS, as a serum biomarker of axonal injury which could prove useful as a prognostic or monitoring tool in the future.

From MSIF

Latest MS research news | 18 March 2014

Evaluating the response to glatiramer acetate in relapsing-remitting MS patients

This study shows that the presence of relapses, with or without MRI activity, in patients treated with glatiramer acetate identifies patients with a higher risk of developing new clinical activity and disability progression over the following years.

From MSIF

Latest MS research news | 18 March 2014

PET imaging of glucose metabolism, neuroinflammation and demyelination in the lysolecithin rat model for MS

The researchers in this study looked at specific disease processes in MS using positron-emission tomography (PET) imaging in small MS-like brain lesions in the rat model.

From MSIF
 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial